SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Direct Operating Costs
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Direct Operating Costs of $142.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DirectOperatingCosts · last filed 2025-02-26
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. direct operating costs for the quarter ending 2024-06-30 was $60.00K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. direct operating costs for the quarter ending 2024-03-31 was $82.00K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. direct operating costs for fiscal 2024 was $142.00K.
| Period end | Direct Operating Costs 1 month | Direct Operating Costs 3 month | Direct Operating Costs 6 month | Direct Operating Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $142.00K 10-K · filed 2025-02-26 | |||
| 2024-06-30 | $142.00K 10-Q · filed 2024-11-13 | $60.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-09-04 | $142.00K 10-Q · filed 2024-09-04 | |
| 2024-03-31 | $82.00K 10-Q/A · filed 2024-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |